Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 2/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1678500 | 0.94 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22363303 | 0.92 | FAAH (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21316483 | 0.92 | FAAH (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Hydrochloric Acid SCHEMBL1950726 | 0.92 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1679043 | 0.92 | FAAH (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24688471 | 0.92 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3036070 | 0.90 | CA1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20372767 | 0.87 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1679032 | 0.86 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22252444 | 0.86 | CA1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694505-B1 | HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3101013-B1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-10640511-B2 | Hepatitis B antiviral agents | Enant Pharmaceuticals, Inc. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190119288-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2019-04-25 | — | — | US | disclosed |
| US-9676760-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9598435-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160347744-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160264577-A1 | HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-09-15 | — | — | US | disclosed |
| US-9346808-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160096846-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20140135317-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20130184255-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2013-01-10 | — | — | US | disclosed |
| US-7923573-B2 | Benzene compound having 2 or more substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-12 | — | — | US | disclosed |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | SANKYO COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1764075-A1 | TISSUE FACTOR PRODUCTION INHIBITOR | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184255-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | PSEN1 2427/4885PSEN2 2503/4885APH1B 3390/4885 |
| US-20190119288-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | PSEN1 1914/4885PSEN2 2679/4885APH1B 580/4885 |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | PTAFR, PLAT, TFPI | PSEN1 372/4885PSEN2 564/4885APH1B 129/4885 |
| US-20160264577-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90B1, HSP90AB2P | PSEN1 3898/4885PSEN2 3935/4885APH1B 4116/4885 |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | PSEN1 2427/4885PSEN2 2503/4885APH1B 3390/4885 |
| US-20160347744-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | PSEN1 2427/4885PSEN2 2503/4885APH1B 3390/4885 |
| US-20140135317-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | PSEN1 2427/4885PSEN2 2503/4885APH1B 3390/4885 |
| US-10640511-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | PSEN1 1914/4885PSEN2 2679/4885APH1B 580/4885 |
| US-20160096846-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | PSEN1 2427/4885PSEN2 2503/4885APH1B 3390/4885 |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | PSEN1 2635/4885PSEN2 1662/4885APH1B 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.